Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
EC grants conditional marketing authorization based on the EFFISAYIL trial
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Subscribe To Our Newsletter & Stay Updated
